Display options
Cite
Chamberlain S, Cole HD, Roque J, et al. TLD1433-Mediated Photodynamic Therapy with an Optical Surface Applicator in the Treatment of Lung Cancer Cells In Vitro. Pharmaceuticals (Basel). 2020;13(7)doi: 10.3390/ph13070137.
Chamberlain, S., Cole, H. D., Roque, J., Bellnier, D., McFarland, S. A., & Shafirstein, G. (2020). TLD1433-Mediated Photodynamic Therapy with an Optical Surface Applicator in the Treatment of Lung Cancer Cells In Vitro. Pharmaceuticals (Basel, Switzerland), 13(7), . https://doi.org/10.3390/ph13070137
Chamberlain, Sarah, et al. "TLD1433-Mediated Photodynamic Therapy with an Optical Surface Applicator in the Treatment of Lung Cancer Cells In Vitro." Pharmaceuticals (Basel, Switzerland) vol. 13,7 (2020). doi: https://doi.org/10.3390/ph13070137
Chamberlain S, Cole HD, Roque J, Bellnier D, McFarland SA, Shafirstein G. TLD1433-Mediated Photodynamic Therapy with an Optical Surface Applicator in the Treatment of Lung Cancer Cells In Vitro. Pharmaceuticals (Basel). 2020 Jun 28;13(7). doi: 10.3390/ph13070137. PMID: 32605213; PMCID: PMC7407920.
Copy Download .nbib Format: NLM
Share it on

Pharmaceuticals (Basel). 2020 Jun 28;13(7). doi: 10.3390/ph13070137.

TLD1433-Mediated Photodynamic Therapy with an Optical Surface Applicator in the Treatment of Lung Cancer Cells In Vitro.

Pharmaceuticals (Basel, Switzerland)

Sarah Chamberlain, Houston D Cole, John Roque, David Bellnier, Sherri A McFarland, Gal Shafirstein

Affiliations

  1. Department of Cell Stress Biology, Photodynamic Therapy Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA.
  2. Department of Chemistry and Biochemistry, The University of Texas at Arlington, Arlington, TX 76019-0065, USA.
  3. Department of Chemistry and Biochemistry, The University of North Carolina at Greensboro, Greensboro, NC 27402-6170, USA.

PMID: 32605213 PMCID: PMC7407920 DOI: 10.3390/ph13070137

Abstract

Intra-operative photodynamic therapy (IO-PDT) in combination with surgery for the treatment of non-small cell lung cancer and malignant pleural mesothelioma has shown promise in improving overall survival in patients. Here, we developed a PDT platform consisting of a ruthenium-based photosensitizer (TLD1433) activated by an optical surface applicator (OSA) for the management of residual disease. Human lung adenocarcinoma (A549) cell viability was assessed after treatment with TLD1433-mediated PDT illuminated with either 532- or 630-nm light with a micro-lens laser fiber. This TLD1433-mediated PDT induced an EC

Keywords: PDT; TLD1433; intra-operative photodynamic therapy; light simulation; optical surface applicator

References

  1. Br J Cancer. 2018 Nov;119(10):1191-1199 - PubMed
  2. Cancer Res. 2004 Mar 15;64(6):2120-6 - PubMed
  3. Proc SPIE Int Soc Opt Eng. 2014 Feb 1;8931: - PubMed
  4. Ann Am Thorac Soc. 2016 Feb;13(2):265-75 - PubMed
  5. Lasers Surg Med. 2020 Jul;52(6):523-529 - PubMed
  6. Ann Thorac Surg. 2017 Mar;103(3):912-919 - PubMed
  7. PLoS One. 2015 Jul 20;10(7):e0133230 - PubMed
  8. Photodiagnosis Photodyn Ther. 2013 Dec;10(4):615-25 - PubMed
  9. Chest. 2014 Dec;146(6):1619-1626 - PubMed
  10. Chem Rev. 2019 Jan 23;119(2):797-828 - PubMed
  11. Semin Thorac Cardiovasc Surg. 2009 Summer;21(2):177-87 - PubMed
  12. Curr Opin Chem Biol. 2020 Jun;56:23-27 - PubMed
  13. J Thorac Dis. 2015 Jun;7(6):1021-30 - PubMed
  14. Photochem Photobiol Sci. 2016 Apr;15(4):481-95 - PubMed
  15. Semin Oncol. 2014 Dec;41(6):820-30 - PubMed
  16. J Biomed Opt. 2018 Aug;23(8):1-11 - PubMed

Publication Types

Grant support